A detailed history of Greenleaf Trust transactions in Biogen Inc. stock. As of the latest transaction made, Greenleaf Trust holds 2,606 shares of BIIB stock, worth $411,487. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,606
Previous 6,081 57.15%
Holding current value
$411,487
Previous $1.41 Million 64.16%
% of portfolio
0.0%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$189.07 - $236.8 $657,018 - $822,880
-3,475 Reduced 57.15%
2,606 $505,000
Q2 2024

Jul 22, 2024

BUY
$190.52 - $236.72 $878,297 - $1.09 Million
4,610 Added 313.39%
6,081 $1.41 Million
Q1 2024

Apr 29, 2024

SELL
$212.02 - $267.71 $145,021 - $183,113
-684 Reduced 31.74%
1,471 $317,000
Q4 2023

Jan 31, 2024

BUY
$222.59 - $267.94 $81,245 - $97,798
365 Added 20.39%
2,155 $557,000
Q3 2023

Nov 09, 2023

BUY
$253.3 - $285.89 $43,314 - $48,887
171 Added 10.56%
1,790 $460,000
Q2 2023

Aug 09, 2023

BUY
$275.25 - $318.06 $5,229 - $6,043
19 Added 1.19%
1,619 $461,000
Q1 2023

May 11, 2023

SELL
$256.56 - $292.34 $62,600 - $71,330
-244 Reduced 13.23%
1,600 $444,000
Q4 2022

Jan 25, 2023

BUY
$252.44 - $306.72 $181,504 - $220,531
719 Added 63.91%
1,844 $511,000
Q3 2022

Nov 10, 2022

SELL
$194.69 - $268.46 $194 - $268
-1 Reduced 0.09%
1,125 $300,000
Q2 2022

Aug 12, 2022

SELL
$187.54 - $223.02 $112,899 - $134,258
-602 Reduced 34.84%
1,126 $230,000
Q1 2022

Apr 27, 2022

SELL
$193.77 - $244.14 $30,809 - $38,818
-159 Reduced 8.43%
1,728 $364,000
Q4 2021

Feb 11, 2022

SELL
$223.92 - $287.77 $339,014 - $435,683
-1,514 Reduced 44.52%
1,887 $453,000
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $367,321 - $479,026
1,298 Added 61.72%
3,401 $962,000
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $47,138 - $75,477
-182 Reduced 7.96%
2,103 $728,000
Q1 2021

Apr 30, 2021

BUY
$242.95 - $284.63 $129,249 - $151,423
532 Added 30.35%
2,285 $639,000
Q4 2020

Feb 08, 2021

SELL
$236.26 - $355.63 $123,327 - $185,638
-522 Reduced 22.95%
1,753 $429,000
Q3 2020

Oct 30, 2020

BUY
$264.77 - $305.71 $96,376 - $111,278
364 Added 19.05%
2,275 $645,000
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $56,129 - $74,333
-217 Reduced 10.2%
1,911 $511,000
Q1 2020

Apr 29, 2020

BUY
$268.85 - $341.04 $138,995 - $176,317
517 Added 32.09%
2,128 $673,000
Q4 2019

Feb 11, 2020

BUY
$220.06 - $304.07 $4,841 - $6,689
22 Added 1.38%
1,611 $478,000
Q3 2019

Nov 08, 2019

SELL
$217.44 - $243.88 $156,774 - $175,837
-721 Reduced 31.21%
1,589 $370,000
Q2 2019

Jul 24, 2019

BUY
$219.29 - $241.72 $89,031 - $98,138
406 Added 21.32%
2,310 $540,000
Q1 2019

May 08, 2019

SELL
$216.71 - $338.96 $141,945 - $222,018
-655 Reduced 25.6%
1,904 $450,000
Q4 2018

Feb 07, 2019

BUY
$278.5 - $352.75 $32,027 - $40,566
115 Added 4.71%
2,559 $770,000
Q3 2018

Oct 29, 2018

BUY
$293.51 - $383.83 $287,639 - $376,153
980 Added 66.94%
2,444 $863,000
Q2 2018

Aug 07, 2018

BUY
$257.52 - $306.91 $164,040 - $195,501
637 Added 77.03%
1,464 $425,000
Q1 2018

Apr 30, 2018

SELL
$260.13 - $367.91 $20,810 - $29,432
-80 Reduced 8.82%
827 $226,000
Q4 2017

Feb 08, 2018

BUY
$307.64 - $344.58 $23,380 - $26,188
76 Added 9.15%
907 $289,000
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $233,635 - $273,972
831
831 $260,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Greenleaf Trust Portfolio

Follow Greenleaf Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.